UPLC-MS/MS Monitoring of Emicizumab Therapy
UPLC-MS/MS Monitoring of Emicizumab Therapy
Active, not recruiting · NCT04472169 · Registry updated 2026-05-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| UPLC-MS/MS Monitoring of Emicizumab Therapy | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Active, not recruiting | Not stated | 2026-05-20 | NCT04472169 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Groupement Interrégional de Recherche Clinique et d'Innovation | 13 |
| University Hospital, Lille | 194 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Chu de Caen | Caen | France | 32 |
| Institut Coeur-Poumon, Pôle d'Hématologie-Transfusion, CHU | Lille | France | 1 |